Orally Delivered CRISPR Therapy, Groundbreaking Evolution
/in CRISPR, Not PCa related, Preclinical Research/by Max225Ac-Macropa-PEG4-YS5: a CD46-Targeted 225Ac Therapy for Prostate Cancer
/in Preclinical Research/by MaxNext-Generation ADCs for Cancer Treatment with Potential in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 16/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! I hope this collection of very promising clinical and preclinical research makes a nice Easter gift for you. Wishing you all a warm hug and a Happy Easter! Stay strong and fight on! As usual, we also have a podcast if […]
Phase1/2: Kesonotide For Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial: GEN1057 Bispecific-Antibody In Metastatic Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxCD-001: A Promising Novel Dual-Targeting Immunotherapy
/in Immunotherapy, Preclinical Research/by MaxSDV2102: A Promising ADC That Targets PSMA Expressing Tumors
/in Antibody-Drug Conjugate, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 27/2026 July 5, 2026
- PARP Inhibition Combined with Targeted T-Cell Activation Drives Polyclonal Antitumor Immunity in mCRPC July 3, 2026
- GPS-ProMPT: Molecular Profiling Identifies Overtreated Prostate Cancer Subgroup July 3, 2026
- RIPCORD Phase 1 Trial: Interim PSMA PET–Guided Adaptive Radiotherapy in Metastatic Castration-Sensitive Prostate Cancer July 2, 2026
